In clinical trials, new antibody therapy controls HIV for months after treatment
3 institutional releases
Published in Nature · View the paper (DOI)
Researchers have developed a novel immunotherapy that can suppress HIV for months at a time, using a combination of two anti-HIV antibodies. The treatment, called broadly neutralizing antibodies (bNAbs), has shown promising results in clinical trials, with some patients experiencing sustained viral suppression for over four months.
Coverage from 3 institutions
- In clinical trials, new antibody therapy controls HIV for months after treatment Rockefeller University · Sep 26, 2018 · first to report
- Combination HIV antibody infusions safely maintain viral suppression in select individuals NIH/National Institute of Allergy and Infectious Diseases · Sep 26, 2018
- Combination antibody therapy results in long-term viral suppression in HIV infection German Center for Infection Research · Sep 27, 2018